Skip to main content

Todos Medical Inks Expanded Deal for 3D Medicines PCR Test Kits in US

NEW YORK — Israeli diagnostics firm Todos Medical said on Friday that it has signed an expanded marketing and distribution deal for 3D Medicines' qPCR test kits, including its SARS-CoV-2 test, in the US.

In March, the companies signed an agreement giving Todos the nonexclusive rights to distribute 3D's 3DMed 2019-nCoV Detection Kit, 3DMed 2019-nCoV & Flu A/B Detection Kit, and Andis350 3DMed Automated Solution real-time PCR machine in the US and Israel. 

Under the new deal, Todos has the exclusive right to pursue Emergency Use Authorization from the US Food and Drug Administration for the SARS-CoV-2 test, which it intends to do this summer, and will have the exclusive US branding and distribution rights to Todos' qPCR test kits.

Todos noted that 3D has recently expanded its extraction reagent manufacturing capacity by adding 1,000,000 extraction reagent production per week, which can be applied to test deployment in the US.

Todos said that it has completed validation of 3D's qPCR kits, preloaded extraction reagents, and automated machines at its partner lab Provista Diagnostics, which it is planning to acquire under an option agreement signed in January, and that it intends to validate in the US 3D's pool testing approach that groups 10 samples together in a single test.   

"We have started to ramp up sales, including a recent marquee sale of our Andis machines to the Cleveland Clinic, and we are now helping our clients get up and running so they can quickly expand their testing capacity," Todos President and CEO Gerald Commissiong said in a statement. "As we move into the next phase of growth for our emerging COVID-19 testing business, we are upselling our growing installed base with Gnomegen qPCR kits and related materials so that Todos can compete effectively with competitors who tend to be focused on national and regional labs in the US."

Additionally, Todos said that it has expanded its international distribution rights to 3D's SARS-CoV-2 testing products to include Singapore, Malaysia, Indonesia, Thailand, Myanmar, Vietnam, Philippines, Cambodia/Laos, Hong Kong, Japan, South Korea, Taiwan, India, United Kingdom, France, Sweden, Italy, Germany, Romania, Austria, Monaco, Switzerland, the Balkans, India, Gulf States, Dubai, UAE, Argentina, Aruba, Bahamas, Barbados, Belize, Bolivia, Mexico, Canada, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Martinique, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Suriname, Trinidad and Tobago, Uruguay, Venezuela, Dominican Republic of Congo, Madagascar, Zimbabwe, Lesotho, Botswana, Angola, Zambia, and South Africa.